이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Shanghai Henlius Biotech 관리

관리 기준 확인 2/4

Shanghai Henlius Biotech's CEO는 Jason Zhu, May2023 에 임명되었습니다 의 임기는 1.08 년입니다. 총 연간 보상은 CN¥ 9.26M, 87.8% 로 구성됩니다. 87.8% 급여 및 12.2% 보너스(회사 주식 및 옵션 포함). 는 HK$ 942.03K 가치에 해당하는 회사 주식의 0.009% 직접 소유합니다. 942.03K. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 4.8 년입니다.

주요 정보

Jason Zhu

최고 경영자

CN¥9.3m

총 보상

CEO 급여 비율	87.8%
CEO 임기	1.2yrs
CEO 소유권	0.009%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Recent updates

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

May 25

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Mar 10

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Dec 31

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 18

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Aug 03

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

May 31

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Apr 06

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 22

CEO 보상 분석

Jason Zhu 의 보수는 Shanghai Henlius Biotech 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	CN¥9m	CN¥8m	CN¥546m

보상 대 시장: Jason 의 총 보상 ($USD 1.28M )은 Hong Kong 시장( $USD 486.88K ).

보상과 수익: Jason 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Jason Zhu (45 yo)

1.2yrs

테뉴어

CN¥9,261,000

보상

Dr. Jun Zhu, also known as Jason, served as President at Shanghai Henlius Biotech, Inc. since November 30, 2021 until October 1, 2023 and its Chief Financial Officer since May 1, 2023 ands serves as its Ex...

리더십 팀

이름	위치	테뉴어	보상	소유권
Wenjie Zhang	Executive Chairman of the Board	4.5yrs	CN¥12.58m	데이터 없음
Jun Zhu	CEO, CFO & Executive Director	1.2yrs	CN¥9.26m	0.0092% CN¥ 1.1m
Huang Wei	President	less than a year	데이터 없음	데이터 없음
Shi-Kau Liu	Co-founder & Head of Strategy Advisory Committee	14.4yrs	CN¥6.21m	0.44% CN¥ 55.2m
Wei-Dong Jiang	Co-Founder & Co-Head of Innovative Advisory Committee	14.4yrs	데이터 없음	0.13% CN¥ 16.5m
Jifeng Zhang	CTO & Senior VP	1.6yrs	데이터 없음	데이터 없음
Miaojie Chen	Vice President of Legal & Compliance Department	1.5yrs	데이터 없음	데이터 없음
Wallis Zeng	VP of Sales & Oncology Business Unit	4.5yrs	데이터 없음	데이터 없음
Junhua Li	VP & Chief Human Resource Officer	2.3yrs	데이터 없음	데이터 없음
Xinjun Guo	Senior Vice President	no data	데이터 없음	데이터 없음
Kurt Yu	Senior VP & Chief Commercial Officer	3.5yrs	데이터 없음	데이터 없음
Cheng Yu	Chief Business Officer & Senior VP	2.7yrs	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: 2696 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Wenjie Zhang	Executive Chairman of the Board	4.5yrs	CN¥12.58m	데이터 없음
Jun Zhu	CEO, CFO & Executive Director	less than a year	CN¥9.26m	0.0092% CN¥ 1.1m
Tak Young So	Independent Non-Executive Director	4.8yrs	CN¥258.00k	데이터 없음
Qiyu Chen	Non-Executive Director	11.5yrs	데이터 없음	데이터 없음
Guoping Zhao	Independent Non-Executive Director	4.8yrs	CN¥258.00k	데이터 없음
Xiaohui Guan	Non-Executive Director	5.6yrs	데이터 없음	데이터 없음
K. Christopher Garcia	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Yifang Wu	Non-Executive Director	9.1yrs	데이터 없음	데이터 없음
Deyong Wen	Non-Executive Director	2yrs	데이터 없음	데이터 없음
Lik Yuen Chan	Independent Non-Executive Director	4.8yrs	CN¥258.00k	데이터 없음
Ruilin Song	Independent Non-Executive Director	4.8yrs	CN¥258.00k	데이터 없음
Rongli Feng	Chairman of Supervisory Board	4.3yrs	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: 2696 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.

Shanghai Henlius Biotech 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Shanghai Henlius Biotech, Inc. Announces Chief Financial Officer Changes

Less than half of directors are independent

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee

Recent updates

Shanghai Henlius Biotech, Inc. Announces Chief Financial Officer Changes

Shanghai Henlius Biotech, Inc. Announces Completion of Phase 1 Clinical Study of a Biosimilar of Daratumumab HLX15 (Recombinant Anti-CD38 Human Monoclonal Antibody

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) agreed to acquire 78.3% stake in Shanghai Henlius Biotech, Inc. (SEHK:2696) from a group of shareholders for CNY 4.3 billion.

Investor sentiment improves as stock rises 19%

Less than half of directors are independent

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

National Medical Products Administration Approves Shanghai Henlius Biotech, Inc.'S the Supplemental Applications of Handayuan (Adalimumab Injection) for the New Indications

Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration (FDA)

Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration

New major risk - Financial position

Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection)

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Shanghai Henlius Biotech, Inc. Receives Approval from United States Food and Drug Administration for Application for Phase 1 Clinical Trial of HLX42 for Injection (Antibody-Drug Conjugate Targeting EGFR with Novel DNA Topoisomerase I Inhibitor)

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13

New minor risk - Financial position

Shanghai Henlius Biotech, Inc. to Report Nine Months, 2023 Results on Nov 15, 2023

Shanghai Henlius Biotech, Inc. Announces Shenzhen Nansiuzhuiang in Combination with Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Shanghai Henlius Biotech, Inc. Announces NMPA Approvals of Two ADC Candidates for IND

Shanghai Henlius Biotech, Inc. Announces the First Patient in Europe Has Been Dosed in the International Multi-Centre Phase 3 Clinical Trial

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication of Hansizhuang (Serplulimab Injection) an Innovative Anti-PD-1 Monoclonal Antibody

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.47 loss in 1H 2022)

Shanghai Henlius Biotech, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee

Consensus EPS estimates fall by 31%

Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Financial Guidance for the Six Months Ended 30 June 2023

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Phase 2 Clinical Trial of HLX26

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

Shanghai Henlius Biotech, Inc. Announces Application for Phase 2 Clinical Trial of Hlx26

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Consensus revenue estimates increase by 13%

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces United States Food and Drug Administration Accepts the Biologic License Application for HLX02

Shanghai Henlius Biotech, Inc. Announces the First Patient in USA Has Been Dosed in Aninternational Multicentre Phase 3 Clinical Study Ofrecombinant Anti-Vegf Humanised Monoclonalantibody Ophthalmic Injection Hlx04-Ofor the Treatment of Wet Age-Related Maculardegeneration (Wamd)

Shanghai Henlius Biotech, Inc. Announces the Phase 1b/2 Clinical Trial of Hlx07

Shanghai Henlius Biotech, Inc. Announces Dosage of First Subject in Phase 1 Clinical Study of HLX15 (Recombinant Anti-CD38 Humanmonoclonal Antibody Injection) in Healthy Chinese Male Subjects

Shanghai Henlius Biotech, Inc. Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC

Shanghai Henlius Biotech Announces the First Patient Dosage in the United States of America in an International Multi-Centre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection)

Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in A Phase 1 Clinical Trialof Hlx60 (Recombinant Humanized Anti-Garp Monoclonalantibody Injection) in Combination with Hansizhuang(Serplulimab Injection) for the Treatment of Advanced Ormetastatic Solid Tumors in Australia

Shanghai Henlius Biotech, Inc. Doses First Patient in A Phase 1 Clinical Trial of anti-TIGIT Fc Fusion Protein HLX53 for the Treatment of advanced/Metastatic Solid Tumours or Lymphomasin Mainland China

Shanghai Henlius Biotech, Inc. Announces the First Patient Was Dosed in NCT05468489

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Bridging Study Comparing Hansizhuang (Serplulimab Injection) Versus Atezolizumab

Shanghai Henlius Biotech, Inc. Announces Hansizhuang (Serplulimab Injection) in Combination with Chemotherapy and Concurrent Radiotherapy Approved to Commence A Phase 3 Clinical Trial

Less than half of directors are independent

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1b/2 Clinical Trial of HLX208

Shanghai Henlius Biotech, Inc. Receives Investigational New Drug Approval from China's National Medical Products Administration for A Phase 2 Clinical Trial of AC101

Shanghai Henlius Biotech, Inc. Announces New Drug Application for New Indication Ofhansizhuang (Serplulimab Injection) in Combination Withchemotherapy for the First-Line Treatment of Squamousnon-Small Cell Lung Cancer Has Been Approved by Thenational Medical Products Administration